Nucleix: Michael Vicari

Nucleix, a Rehovot, Israel-based liquid biopsy company, has appointed Michael Vicari as chief commercial officer to lead commercialization efforts for the firm's Lung EpiCheck blood test for early lung cancer. Vicari joins Nucleix from Grail, where his team launched the Galleri multi-cancer early detection assay. Prior to Grail, Vicari held senior level commercial positions at Inivata, OncoCyte, Sequenom, Monogram Biosciences, and Genentech.